{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:19:14Z","timestamp":1793013554195,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ophtha.2014.10.013","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:06:16Z","timestamp":1420675576000},"page":"769-778","source":"Crossref","is-referenced-by-count":64,"title":["Therapies for Macular Edema Associated with\u00a0Central Retinal Vein Occlusion"],"prefix":"10.1016","volume":"122","author":[{"given":"Steven","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Schoenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Bakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justis P.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.10.013_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0039-6257(93)90138-W","article-title":"Central retinal vein occlusion in young adults","volume":"37","author":"Fong","year":"1993","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib3","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/j.1755-3768.2011.02292.x","article-title":"Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion","volume":"90","author":"Koss","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.10.013_bib5","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"suppl","key":"10.1016\/j.ophtha.2014.10.013_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0039-6257(84)90228-5","article-title":"Macular edema secondary to occlusion of the retinal veins","volume":"28","author":"Gutman","year":"1984","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib7","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.1989.01070020367037","article-title":"Macular grid photocoagulation for macular edema in central retinal vein occlusion","volume":"107","author":"Klein","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report","volume":"102","author":"Central Vein Occlusion Study Group","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1442-9071.2009.01909.x","article-title":"Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion","volume":"36","author":"Park","year":"2008","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib10","doi-asserted-by":"crossref","first-page":"18902","DOI":"10.1073\/pnas.0509069102","article-title":"A\u00a0therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165","volume":"102","author":"Lee","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2014.10.013_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archophthalmol.2009.14","article-title":"Pegaptanib sodium for macular edema secondary to central retinal vein occlusion","volume":"127","author":"Wroblewski","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.10.013_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2014.10.013_bib14","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2014.10.013_bib15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/112067210901900625","article-title":"Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion","volume":"19","author":"Raszewska-Steglinska","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00006982-200603000-00009","article-title":"Radial optic neurotomy with adjunctive intraocular triamcinolone for central retinal vein occlusion: 63 consecutive cases","volume":"26","author":"Opremcak","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.10.013_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00006982-200603000-00008","article-title":"Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases","volume":"26","author":"Opremcak","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.10.013_bib18","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ophtha.2009.10.026","article-title":"The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion","volume":"117","author":"McAllister","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib19","article-title":"Central Vein Occlusion Study Group. Central vein occlusion study of photocoagulation therapy: baseline findings","year":"1993","journal-title":"Online J Curr Clin Trials"},{"key":"10.1016\/j.ophtha.2014.10.013_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib22","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib24","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/IAE.0b013e3182647f69","article-title":"Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide","volume":"33","author":"Zacharias","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.10.013_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to\u00a0central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib30","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ophtha.2012.01.022","article-title":"Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib31","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.ophtha.2012.06.037","article-title":"Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/jop.2011.0050","article-title":"Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial","volume":"27","author":"Zhang","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2014.10.013_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/IAE.0b013e3181f4420d","article-title":"Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion","volume":"31","author":"Ding","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.10.013_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000338732","article-title":"Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema","volume":"228","author":"Mayer","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2014.10.013_bib37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00417-012-2134-1","article-title":"A\u00a0prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) Study Group","volume":"251","author":"Aggermann","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00417-009-1187-2","article-title":"Venous retinal flow reperfusion mechanisms following radial optic neurotomy with adjunctive intraocular triamcinolone in central retinal vein occlusion","volume":"248","author":"Fortunato","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.survophthal.2010.11.006","article-title":"Retinal vein occlusion: beyond the acute event","volume":"56","author":"Ehlers","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2008.10.024","article-title":"Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion","volume":"147","author":"DeCroos","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007990903439046","article-title":"Resource use and costs of branch and central retinal vein occlusion in the elderly","volume":"26","author":"Fekrat","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ophtha.2014.10.013_bib44","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.ophtha.2010.12.034","article-title":"Economic considerations of macular edema therapies","volume":"118","author":"Smiddy","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.10.013_bib45","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.121.9.1297","article-title":"Vision-related quality of\u00a0life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire","volume":"121","author":"Deramo","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.10.013_bib46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/IAE.0b013e31802c0a34","article-title":"Patients\u2019 preferences in choosing therapy for retinal vein occlusions","volume":"27","author":"Chang","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.10.013_bib47","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after\u00a0retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014010136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014010136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T07:39:49Z","timestamp":1566200389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014010136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0161642014010136"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.10.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}